Privately held Italian drugmaker Menarini Group said on Monday it would buy U.S. company Stemline Therapeutics Inc in a deal valued at up to $677 million, looking to gain access to a U.S. approved drug for a rare blood...
Japan’s Takeda sells $670 million of Europe OTC assets to pare debt
Japan’s Takeda Pharmaceutical Co Ltd said it would sell up to $670 million of over-the-counter drug operations in Europe to pare debt ahead of its full-year earnings announcement. Takeda, Japan’s biggest pharma company...
Japan’s Takeda plans to sell consumer health unit for around $3.7 billion – Nikkei
Japan’s Takeda Pharmaceutical Co Ltd plans to sell its consumer health unit for around 400 billion yen ($3.72 billion), Nikkei Business reported. Possible buyers of Takeda Consumer Healthcare Co include Taisho...
EU clears Mylan’s purchase of Pfizer’s Upjohn unit with conditions
The European Commission said on Wednesday it had approved generic drugmaker Mylan NV’s planned purchase of Pfizer’s off-patient branded drugs business Upjohn, subject to conditions. The Commission, which oversees...
GSK, Sanofi team up to bring out Covid-19 vaccine
Two of the world’s largest vaccine manufacturers, Sanofi and GlaxoSmithKline, are coming together to work on a COVID-19 vaccine, which if it passes the clinical trials would become available by 2021. Sanofi and...
Alnylam’s gene-silencing efforts get $2 billion Blackstone backing
Blackstone Group Inc said on Monday it would invest $2 billion in Alnylam Pharmaceuticals Inc through an equity-and-debt deal, giving the drugmaker a financial boost without tapping into currently volatile stock markets...
Johnson & Johnson abandons deal for Takeda’s TachoSil surgical patch
Johnson & Johnson said on Friday it abandoned plans to buy Takeda Pharmaceutical’s surgical patch product TachoSil, citing regulatory issues. Takeda, Japan’s biggest drugmaker, announced the sale of TachoSil, a...
TPG, KKR in race to buy 20% stake in Piramal pharma biz
American private equity giants TPG Capital and KKR & Co. Inc. have emerged as the front runners to invest ₹3,500-4,000 crore for acquiring a 20% stake in Piramal Group’s proposed pharmaceutical entity that would...
Orchid Pharma approves amalgamation of Dhanuka Pharma with itself
The monitoring committee of Orchid Pharma Ltd (OPL) has approved the amalgamation of Dhanuka Pharmaceuticals Pvt Ltd (DPPL) into the company, and has issued 10,000 equity shares of OPL with a face value of Rs 10 each to...
Novartis scraps sale of assets including Covid-19 drug to Aurobindo Pharma
Novartis AG on Thursday scrapped the $1 billion sale of US generic pill and skin drug assets to India’s Aurobindo Pharma Ltd as regulators balked, setting back the Swiss drugmaker’s shift to more profitable...
Aurobindo Pharma calls off $1 billion deal with Sandoz after failing to get FTC nod
Hyderabad based generic drug maker Aurobindo Pharma Ltd on Thursday said that it is calling off its proposed acquisition of the US dermatology business and three manufacturing units of Sandoz, a division of Swiss drug...
Drugmakers Mylan, Pfizer delay merger due to coronavirus outbreak
Drugmaker Mylan NV’s merger with Pfizer Inc’s off-patent branded drug unit, Upjohn, will now close in the second half of this year, the companies said on Thursday, blaming the coronavirus pandemic for the delay. Due to...
